Salute e Benessere
Leucid Bio Provides Update on Phase I/IIa AERIAL Trial Evaluating Lateral CAR-T LEU011 for the Treatment of Solid Tumours
To date, treatment with LEU011 has been generally well tolerated. In addition, disease control (based on RECIST criteria) has been observed in multiple patients treated with the lowest dose of LEU011 . Dose-escalation in the AERIAL trial continues as planned, with additional data from the trial anticipated during the first half of 2026.
AERIAL is a multi-centre, dose-escalation trial designed to evaluate the safety and clinical activity of LEU011 in patients with relapsed/refractory solid tumours, following a single intravenous dose of LEU011 after preconditioning chemotherapy. Additional information on the AERIAL trial can be found on ClinicalTrials.gov under the identifier NCT06193902.
Details of the ongoing AERIAL trial were presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2025.
A First-in-human Phase I/IIa dose escalation trial evaluating the safety and preliminary efficacy of
LEU011 , a novel CAR-T, in subjects with relapsed/refractory solid tumors (AERIAL)
R. Kristeleit
Clinical Trials In Progress
Saturday, November 8, 2025
578
LEU011 is a lateral CAR-T cell therapy targeting NKG2D stress ligands, which are overexpressed on more than 80% of human tumour cells and the cells within the surrounding tumour microenvironment. In addition to its novel architecture, LEU011 also co-expresses the chemokine receptor CXCR2 which is engineered to enhance cell trafficking and tumour infiltration, providing an extra mechanism to overcome significant limitations of CAR-T therapies currently in development for the treatment of relapsed/refractory solid tumours.
Leucid Bio is a privately-held biotechnology company dedicated to the development of cell therapies for the treatment of solid tumours using the Company's proprietary lateral CAR platform. The Company's lead asset, LEU011 , is a CAR-T cell therapy for the treatment of solid tumours. For more information, please visit the Leucid Bio website at www.leucid.com.
View original content:https://www.prnewswire.co.uk/news-releases/leucid-bio-provides-update-on-phase-iiia-aerial-trial-evaluating-lateral-car-t-leu011-for-the-treatment-of-solid-tumours-302608960.html